Antagonism of CXCR7 with a targetted monoclonal antibody can effectively ameliorate both cardiac and renal fibrosis and may represent an anti-fibrotic therapy in the setting of mineralocorticoid excess. Here, ACKR3 is linked to renal fibrosis.